Optimal Dosing of 5-Aminosalicylic Acid: 5 Decades of Choosing Between Politicians

The right dose differentiates a poison and a remedy.

— Paracelsus

5-Aminosalicylic acid (mesalamine) delivered to the colon by sulfasalazine (SASP) was advanced as therapy for ulcerative colitis (UC) in 1952.[1] Mesalamine and SASP are effective in the induction and maintenance of remission in UC; this is robustly supported by placebo- controlled trials. Unfortunately, however, the story of the mesalamine delivery systems and recommended doses from 1952 to the present time has not followed a logical, step-wise evolution to an ideal approach but rather resembles a series of political campaigns. As Otto von Bismarck, the Prussian statesman, stated in 1863, “Politics is not an exact science.” It is common practice to lump mesalamine preparations together but to consider them separately from SASP. Within the mesalamine class, we have been presented with a variety of products: arrays of paired active molecules; prodrugs, custom-designed coatings; specialized granule design. Differences in the chemistry, delivery systems, and bioavailability of these specific products have made it diffi- cult to sort out whether mesalamine is truly superior to SASP and more specifically whether a particular mesalamine delivery system is best.

“More is better” is a central theme and is based on the dose-response relationship observed with SASP in doses up to 4 g/day.[2] Many clinicians have used upward titration of SASP to the highest tolerated dose to induce remission followed by downward titration to a dose that minimized side effects for long-term maintenance therapy. In clinical practice, this strategy has been applied to various mesalamine preparations for which on careful scrutiny of the available data, a dose-response relationship may not be so clear.

A systematic review of mesalamine for the induction of remission in UC found only a trend to a significant dose response.[3] In the PROBE trial examining type and dose of mesalamine for maintenance of remission in 388 patients with UC, mesalamine as Asacol 2 g/day and Salofalk 2 g/day showed equivalence, and no additional benefit was seen from higher dosing with 3.2 g of Asacol.[4]

In this issue of Clinical Gastroenterology and Hepatology, Kruis et al.5 describe their experience in an international industry-funded investigation of one of the latest candidate mesalamine agents. They examined the efficacy of a new mesalamine pellet preparation administered as a sachet 3 times daily in equal doses for 8 weeks. These pellets are designed to offer both delayed and sustained release to target the colon. Three hundred nineteen patients were randomized to daily dosing with 1.5, 3.0, or 4.5 g. The primary end point was clinical remission rate at 8 weeks, and the study was powered accordingly. At 8 weeks, all groups had similar remission and improvement rates, with clinical remission ranging from 50% to 60%. They conclude that there is no significant dose response between 1.5, 3, or 4.5 g per day and suggest that the optimal dose for mesalamine is 0.5 g 3 times a day (1.5 g).

Kruis et al. are to be praised for controlling concomitant medications, choosing a primary end point, performing a power analysis, and then faithfully reporting the outcome of the study. Unfortunately, their conclusions do not end the debate over dose-response curves for this class of drugs. For example, in this particular trial, the clinician and patient will also be interested in more details of the median time to onset of action for each treatment arm. Most would concur that suffering 26 days of diarrhea (as was seen in the group randomized to 1.5 g per day) would be worse than the 15 days of diarrhea observed in the highest dose group. The study subjects seemed to agree that this outcome was important; many voted with their feet, with 23% dropping out most often for “inefficiency of treatment” in the lowest dose group compared to 10% in the 4.5-g dose group. The 1.5-g dose group also suffered more adverse events than the higher dose groups, presumably because of classification of inefficiency of treatment as an adverse event. In addition, this study does not answer the question of whether patients treated with 1.5 or 3.0 g/day who fail to respond then subsequently respond if the mesalamine dose is escalated to 4.5 g/day.

How should the clinicians incorporate the information from this study into their practice? We suggest that they look at these data carefully. With further investigation of this agent, it is likely that there will be differences demonstrated between efficacy, where conclusions are made in the controlled construct of a study, and effectiveness, where conclusions are drawn from how an agent performs in clinical practice. For this particular delivery system (specialized pellets administered as a sachet) in a controlled trial setting (8-week observation period), the difference in clinical remission rates between doses was not significant. In practice, the relatively large number of pills required for the recommended dose of many of the commercial products in this class and the patient’s inclination to opt for speedier (albeit more toxic) agents will also influence our perception of the candidate medication. In the meantime, this particular campaign reminds us to continue to question whether more is truly better. As we embrace information based on evidence, we should avoid falling into the trap of practical politics and heed the admonition of the U.S. historian Henry Adams, “Practical politics consists in ignoring facts.”

STEPHEN J . BICKSTON, M.D. FABIO COMINELLI, M.D., PH.D.

University of Virginia Digestive Health Center of Excellence Charlottesville, Virginia

References

1. Morrison LM. Results of treatment of ulcerative colitis with salicylazosulfapyridine. Gastroenterology 1952;21:133– 138.

2. Hanauer SB. Aminosalicylates therapy for ulcerative colitis. In: Bayless TM, Hannauer SB, eds. Advanced therapy of in- flammatory bowel disease. 2nd ed. Hamilton, Ontario: B. C. Decker, 2001.

3. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2002;3:CD000543.

4. Deventer SJH, Hommes DW, Roskam Mul MDM, Dekker W, Wetzels A, Nelis F, Engels Z, Snel P, Schook G, Meuwissen SGM, Tytgat GNJ. Prospective randomized open-label blinded endpoint (PROBE) trial of high- versus low-dose mesalazine for prevention of relapse in patients with ulcerative colitis in remission (abstr). Gastroenterology 2001; 120:A454.

5. Kruis W, Bar-Meir S, Feher J, Mickisch O, Mlitz H, Arber N, Faszczyk M, Chowers Y, Lengyele G, Kovacs A, Lakatos L, Stolte M, Vieth M, Greinwald R, for the International Salofalk Pellets Study Group. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003;1:36–43.

News about Crohn's Disease

Channel: Crohn's News From Medical News Today

• Life Begins At 40 For NHS Occupational Therapist Who Suffered From Crohn's Disease

Cardiff has the highest incidence of Crohn's Disease in the UK. The University Hospital of Wales is conducting research into the condition with eminent gastroenterologist Dr Hawthorne of Cardiff and Vale NHS Trust who himself is part of a national study. Researchers are analysing data from the last 25 years in an attempt to explain what could cause the condition to be more prevalent in Cardiff isolating such factors as diet, bacterial infection and genetic impact.
• Pathogen That Causes Disease In Cattle Also Associated With Crohn's Disease - Research Urgently Needed To Evaluate Potential Risks To Humans

People with Crohn's disease (CD) are seven-fold more likely to have in their gut tissues the bacterium that causes a digestive-tract disease in cattle called Johne's disease. The role this bacterium may or may not play in causing CD is a top research priority, according to a new report released by the American Academy of Microbiology.
• Pill Cam SB Could Help Doctors Treat Children With Crohn's

According to a study released on July 9, 2008 in the Journal of Pediatric Gastroenterology and Nutrition, PillCam capsule endoscopy in the small intestines may improve Crohn's Disease treatment regimens in children by assisting in appropriate classification of inflammatory bowel diseases. Inflammatory bowel diseases (IBD) are a set of chronic inflammatory diseases of the intestinal tract.
• Drug For Treatment Of Inflammatory Bowel Disease - New Formula Allows For Greater Absorption, Fewer Doses

Physician-scientists from NewYork-Presbyterian/Weill Cornell, involved in clinical trials for a new drug for those who suffer from inflammatory bowel disease (IBD), say it is the best option among available drugs. Gaizo is a reformulation of the active ingredient 5-ASA in currently available drugs. However, the researchers found that 99 percent of the active ingredient in the new pill is released in the colon compared to only 70 percent in other common IBD drugs. Dr.
• Stem Cells Heal Chronic Inflammation In The Gut - May Help Restore Immune System To Normal Function For Crohn's Disease

Stem cells are being studied at NewYork-Presbyterian/Weill Cornell to heal the gut in subjects suffering from Crohn's disease. Physician-scientists believe that these cells might help to restore the ability of the immune system to control inflammation by secreting anti-inflammatory proteins into the digestive tract, allowing for regeneration of tissue and prevention of scar tissue.
• New Therapies And Medications For Crohn's Disease

A New Drug Class article released on July 4, 2008 in The Lancet seeks to highlight a new group of drugs intended to treat Crohn's disease. Most current drugs seek to control the autoimmune response via the tumor necrosis factor alpha (TNF-alpha), but many new classes attempt to control other aspects of the immune response or even to reinforce the intestinal barrier itself.
• International Team Identifies 21 New Genetic Risk Factors For Crohn's Disease

An international consortium of Crohn's disease researchers has combined data from three independent studies to identify 21 new genetic variants associated with the inflammatory bowel disorder, bringing the total number of risk factors to 32. Several of these are involved with the immune system's inital response to pathogens, supporting earlier evidence that disruptions in a process called autophagy may lead to the disorder's characteristic immune system overactivity.
• Complexity Of Crohn's Disease Revealed As 'gene' Count Tops 30

New research has trebled the number of genetic regions known to be implicated in Crohn's disease, a form of inflammatory bowel disease, to over thirty. The research, published in the journal Nature Genetics, has identified a number of potential new targets for drug development as well as providing surprising new links between the condition and other common diseases including asthma.
• Study Underway To Find An Alternative Cure For Crohn's Disease And Ulcerative Colitis

Two research studies evaluating dietary changes and complementary medicine for the treatment of inflammatory bowel diseases (IBD) have been launched at Rush University Medical Center. Funded by the National Institute of Health, one study will look at the impact of mind/body medicine on patients suffering from ulcerative colitis (UC) and the other will assess how diet impacts patients with Crohn's Disease.
• Studies Seeking Subjects: Alternative Remedies For Ulcerative Colitis And Crohn's Disease

There are two new research studies commencing regarding inflammatory bowel diseases (IBD) at Rush University Medical Center. These studies plan to investigate the impact of mind related medicine on patients suffering from ulcerative colitis (UC) and the impact of diet on Crohn's Disease (CD.) Inflammatory bowel diseases (IBD) are a set of chronic inflammatory diseases of the intestinal tract.
• ChemoCentryx Completes Enrollment Of PROTECT-1, A Phase II/III Clinical Trial Of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) In Crohn's Disease

ChemoCentryx, Inc., announced the completion of enrollment of 436 patients in the company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial), a Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease.
• New Way To Fight Inflammation Discovered At Oxford

Researchers at the University of Oxford have discovered a series of new peptide molecules that have potential as treatments of inflammatory disorders, including endotoxic shock, inflammatory bowel disease, rheumatoid arthritis, uveitis and atherosclerosis.
• FDA Investigating Arthritis Drugs And Cancer Risk In Children

The US Food and Drug Administration (FDA) is investigating a possible link between tumor necrosis factor (TNF) blockers, a class of drugs for treating arthritis and other conditions, and cancer risk in children. In an early communication issued yesterday, 4th June, the FDA's Center for Drug Evaluation and Research (CDER) said it was investigating the possible link between TNF blockers and the development of lymphoma and other cancers in children and young adults.
• Studying Bacterial Communities Inside Us To Better Understand Health And Disease

The number of bacteria living within the body of the average healthy adult human are estimated to outnumber human cells 10 to 1. Changes in these microbial communities may be responsible for digestive disorders, skin diseases, gum disease and even obesity.
• Discovery Of New Family Of Genetic Mutations Involved In Inflammatory Intestinal Disease

The discovery of new genetic mutations involved in inflammatory intestinal disorders could lead to a better understanding of these common conditions, two scientists told the annual conference of the European Society of Human Genetics on 2 June. Dr.Alexandra Zhernakova, from the Utrecht University Medical Centre, Utrecht, the Netherlands, and Dr.
• Pluristem Demonstrates The Potential Of Its PLX Cells To Treat Crohn's Disease And Ulcerative Colitis

Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced that the Company's PLacental eXpanded (PLX) cells have demonstrated in vivo efficacy in the treatment of Crohn's Disease and Ulcerative Colitis, collectively termed Inflammatory Bowel Disease (IBD).
• Abbott Presents Long-term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA® (adalimumab) Maintained Remission

Results from an open-label extension study of two Abbott pivotal studies, CHARM and GAIN, demonstrate that adult moderate-to-severe Crohn's patients treated with HUMIRA® (adalimumab) achieved long-term clinical remission and clinical response, respectively, according to data presentations at Digestive Disease Week® (DDW) in San Diego.
• Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission

Results from an open-label extension study of two Abbott pivotal studies, CHARM and GAIN, demonstrate that adult moderate-to-severe Crohn's patients treated with HUMIRA(R) (adalimumab) achieved long-term clinical remission and clinical response, respectively, according to data presentations at Digestive Disease Week(R) (DDW) in San Diego.
• HUMIRA Improves Remission In Crohn's Patients

An open-label extension study of the CHARM and GAIN studies, performed in Abbott labs, demonstrate that patients with moderate-to-severe Crohn's disease who are treated with HUMIRA® (adalimumab) actually achieved long-term clinical remission and a full clinical response respectively. This information was presented on May 21, 2008 at Digestive Disease Week® (DDW) in San Diego.
• New Analysis Of REMICADE For UC In Patients With Recent Disease Onset Or Long-Standing Disease

Data from a new analysis of the Active Ulcerative Colitis Trials (ACT 1 and ACT 2) showed that at week 8, more than 60 percent of patients with moderately to severely active ulcerative colitis (UC) receiving REMICADE® (infliximab) achieved clinical response regardless of disease duration (less than three years versus at least three years).
• FDA Approval Of Cimzia(R) For Crohn's Disease Represents Latest Milestone For Nektar's PEGylation Technology Platform

The U.S. Food and Drug Administration (FDA) approved UCB's Cimzia(R) (certolizumab pegol) for reducing the signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy. Cimzia(R) is the first and only PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody approved by the FDA.
• Cimzia® Approved In United States For Crohn's Disease

According to a press release from UCB on April 22, 2008, a new pegylated anti-TNFα, will be made available in the United States under the name Cimzia® in the next few days. This will be a new, promising option for patients suffering from moderate to severe Crohn's Disease. Crohn's Disease (CD) is a gastrointestinal disorder which is indicated by chronic inflammation of the wall of the digestive tract, usually in the ileum or large intestines.
• FDA Approves Cimzia To Treat Crohn's Disease

A new drug has been approved to help sufferers of Crohn's disease, the U.S. Food and Drug Administration announced today. Cimzia (certolizumab pegol) received approval for adults with moderate to severe Crohn's disease who have not responded to conventional therapies. This product was approved with a Medication Guide. Crohn's disease is a chronic, inflammatory bowel disease that affects more than 1 million men and women worldwide. It has no cure and its cause is unknown.
• Omega-3's No Help For Crohn's Sufferers

An international study led by Dr. Brian Feagan of Robarts Research Institute at The University of Western Ontario in London, Canada has found that omega-3 fatty acids are ineffective for managing Crohn's disease. The research is published in the April 9 Journal of the American Medical Association.
• For Crohn's Patients, Omega-3 Fatty Acids Not Effective In Preventing Relapse

Administration of omega-3 fatty acid supplements did not appear to improve the rate of relapse in patients with Crohn's disease, according to a study released on April 9, 2008 in JAMA. Crohn's Disease is a gastrointestinal disorder which is indicated by chronic inflammation of the wall of the digestive tract, usually in the ileum or large intestines.